NOVO
Novo Nordisk A/S Shs Unsponsored Canadian Depository Receipt Hedged · NEO:NOVO
17.27 CAD0.5800 +3.48%
Novo Nordisk A/S Shs Unsponsored Canadian Depository Receipt Hedged (NEO:NOVO) last traded at 17.27 CAD, up 3.48% on the day. Over the past year the stock is down 15.71%. Its 52-week range is 14.94 to 26.74. It is in the Health Technology sector (Pharmaceuticals: Major).
Key statistics
Open17.25
Day range17.19 – 17.27
52-week range14.94 – 26.74
Volume1.20 K
Average volume (10 days)650
Market cap (USD)175.64 B
P/E3.05
EPS (TTM) (USD)3.99
Dividend yield4.40%
Beta (1 year)0.7215
Revenue (TTM) (USD)50.21 B
Employees68.79 K
Performance
+2.98%1 week
−3.03%1 month
−17.37%3 months
−1.65%6 months
−19.79%Year to date
−15.71%1 year
Technical rating
Sell
Daily summary of 11 oscillators and 15 moving averages. See every indicator
Latest headlines
- Weekly Recap: Wegovy scripts 265k+ and injunction denied in Eli Lilly ad suitTradingView · 02 Nov 2026
- Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up NextStocktwits · 02 Nov 2026
- Jobs, Midterm Elections, Apple, Palantir, McDonald's, Moderna, and More to Watch This Week — Barrons.comDow Jones Newswires · 01 Nov 2026
- Healthcare Earnings Scoreboard: 96% beat EPS estimates, 70% post Y/Y earnings growthSeeking Alpha · 31 Oct 2026
- Steve Jobs' Son Says GLP-1 Weight Loss Drugs Could Be Among Most Important Medicines Ever, With Potential Impact on CancerBenzinga · 29 Oct 2026
- Lilly's retatrutide outshines Ozempic on weight loss, blood sugar control in trialReuters · 28 Oct 2026
- Novo Nordisk Loses Court Bid Against Eli Lilly’s Weight-Loss Drug Ads — Judge Says Sales Impact Was Negligible (UPDATED)Benzinga · 28 Oct 2026
- LLY Vs NVO: Lilly’s Retatrutide Beats Novo’s Ozempic In Head-To-Head Trial — Retatrutide More Than Doubles Weight LossStocktwits · 28 Oct 2026
Market data from TradingView’s public feed, delayed as the exchange requires. For study only, not investment advice.